GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection. - Degroote L; Chrzanowski J; Lemaitre P; Wouters A; Bourgeois S; Van Mulders A; Pierreux J; Coenen S; Willems L; Leuckx G; Viaene M; Packbier M; et al. (Diabetologia, 2026)